Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists
- 17 April 2012
- journal article
- review article
- Published by SAGE Publications in Annals of Pharmacotherapy
- Vol. 46 (5) , 710-717
Abstract
Objective: To review drug interaction studies of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and concurrent oral medications. Data Sources: PubMed was searched (to December 5, 2011) using the terms exenatide, liraglutide, albiglutide, and lixisenatide. The search was limited to studies published in English and conducted in adults. Abstracts from the American Diabetes Association Scientific Sessions from 2004 through 2011 were also searched. Study Selection and Data Extraction: All abstracts were screened for eligibility, which consisted of studies reporting the effects of GLP-1 RA administration on the pharmacokinetics and pharmacodynamics of concurrent oral medications. Data extracted from eligible trials included study and population characteristics; pharmacokinetic parameters including maximum concentration (C max ,), time to maximum concentration (t max ), and area under the concentration-time curve (AUC); and pharmacodynamic properties. Data Synthesis: Our search identified 254 potentially relevant articles; of those, 11 articles evaluating 15 drug interactions were reviewed. Only 1 study was conducted in patients with type 2 diabetes. Equivalence in AUC was demonstrated in the majority of drug interactions studied (11 of 15). The AUCs of acetaminophen and lovastatin were decreased after exenatide administration and those of lisinopril and digoxin were decreased after liraglutide administration. In 10 studies, GLP-1 RAs decreased the C max and, in 14 studies, prolonged the t max of study drug. Pharmacokinetic properties of drugs and differences in study design can explain differences in interaction potential. Conclusions: GLP-IRAs may produce clinically significant interactions with drugs that require achievement of target peak concentrations or a rapid onset of action. Studies in patients with type 2 diabetes are needed to further assess and allow comparison of several GLP-1 RA agents’ impact on steady-state pharmacokinetics and pharmacodynamics of concomitant oral medications.Keywords
This publication has 15 references indexed in Scilit:
- Treatment With Liraglutide-a Once-Daily GLP-1 Analog-Does Not Reduce the Bioavailability of Ethinyl Estradiol/Levonorgestrel Taken as an Oral Combination Contraceptive DrugThe Journal of Clinical Pharmacology, 2011
- National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2·7 million participantsThe Lancet, 2011
- Clinical Pharmacology of Incretin Therapies for Type 2 Diabetes Mellitus: Implications for TreatmentClinical Therapeutics, 2011
- An overview of once‐weekly glucagon‐like peptide‐1 receptor agonists—available efficacy and safety data and perspectives for the futureDiabetes, Obesity and Metabolism, 2011
- Dose‐dependent effects of the once‐daily GLP‐1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double‐blind, placebo‐controlled trialDiabetic Medicine, 2010
- The effect of exenatide on lisinopril pharmacodynamics and pharmacokinetics in patients with hypertensionInt. Journal of Clinical Pharmacology and Therapeutics, 2009
- Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority studyThe Lancet, 2008
- Effect of Exenatide on the Pharmacokinetics and Pharmacodynamics of Warfarin in Healthy Asian MenThe Journal of Clinical Pharmacology, 2006
- Effects of Exenatide (Exendin-4) on Glycemic Control Over 30 Weeks in Sulfonylurea-Treated Patients With Type 2 DiabetesDiabetes Care, 2004
- Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDMDiabetologia, 1996